Vaxart Q4 2023 Earnings Report
Key Takeaways
Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022. Revenue for the full year 2023 was $7.4 million, compared to $0.1 million for 2022. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
Vaxart made significant progress in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator
Topline data from Phase 1 norovirus study in lactating mothers expected in mid-2024
Steven Lo appointed President, Chief Executive Officer and Board Member
BARDA awarded Vaxart a $9.27 million contract in January to prepare for a 10,000-subject, Phase 2b clinical study
Vaxart
Vaxart
Forward Guidance
Vaxart anticipates cash runway into the fourth quarter of 2024.